Drug Trial Radar · NCT05017987
Clinical Trial to Compare Pharmacokinetics After Administration of ATB-101 or Co-administration of ATB-1011 and ATB-1012
Last checked: Nov 19, 2026Latest source record: Jan 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Jun 19, 2021
Primary completion
Jul 12, 2021
Study completion Jul 12, 2021
Sponsor
- Lead sponsor
- AutotelicbioIndustry
- Sponsor type
- Industry
- First posted
- Aug 24, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To compare and evaluate safety and pharmacokinetic Characteristics after administration of ATB-101 or co-administration of ATB-1011 and ATB-1012 in fasted Healthy Adult Volunteers
Conditions
- Healthy Adult Volunteers
Interventions
ATB-101, ATB-1011, ATB-1012Drug
1. Test drug \- Code name: ATB-101 2. Control drug1 * Code name: ATB-1011 * Active ingredient: Olmesartan 3. Control drug2 * Code name: ATB-1012 * Active ingredient: Dapagliflozin
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUCt of OlmesartanTime frame: Day1(first stage), Day8(scond stage)
- Cmax of OlmesartanTime frame: Day1(first stage), Day8(scond stage)
- AUCt of DapagliflozinTime frame: Day1(first stage), Day8(scond stage)
- Cmax of DapagliflozinTime frame: Day1(first stage), Day8(scond stage)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
H Plus Yangji Hospital
Seoul, Gwanak-gu, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.